3 results
Approved WMORecruiting
Evaluation of the effect of treatment with the Meniett in patients with unstable Menière*s disease.
Approved WMORecruiting
To evaluate the ongoing safety, tolerability, and efficacy parameters of pegunigalsidase alfa in adult Fabry patients who have successfully completed studies PB-102-F20 and PB-102-F30, or completed at least 48 months in study PB-102-F03.
Approved WMORecruiting
This prospective, randomized, controlled, unblinded, multicenter study aims at comparing procedural time between conventional CLOSE-guided PVI (35W/50W) versus very high power radiofrequency delivery (90W) in AF patients scheduled for a first PVI.